Clinical Trial

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Recruiting
View on ClinicalTrials.gov →
Summary
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) for patients with Uveal Melanoma that has metastasized to the liver.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-21.
Status change: Not Yet Recruiting → Recruiting 2026-03-09
Trial Details
NCT Number NCT07364474
Lead Sponsor Massachusetts General Hospital
Conditions Uveal Melanoma
Enrollment 10 participants
Start Date 2026-01-27
Primary Completion 2027-12 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-11